Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors

Product is added to your Wishlist
Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market

Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2016-2023 (Focus on Biomarker Test Type, Application & Market Trends)

The global emerging cancer diagnostics market is expected to grow at a CAGR of 13.45% from 2016 to 2023 and reach a figure of $6.34 billion by 2023. The advancements in technology, adoption of biomarker tests, and increasing cancer incidence rate are some of the major driving factors for this market. The global emerging cancer diagnostics market has been classified on the basis of test type, application and geography.

SKU: BH013A
Published Year: 2017
 
 

Cancer is a chronic disease and is affecting a huge population. Many technologies are emerging in the cancer diagnostics market. This report is focused on emerging cancer diagnostics market specifically on biomarker tumor test. The market growth is propelled due to factors such as: increasing number of cancer cases, technological innovation and advancements, increasing awareness among people, and medicare & reimbursement policies, among others. 

This study includes an overview and analysis of the emerging cancer diagnostics market, by test type, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of cancer, their incidence and prevalence rate has been discussed in the report. All of the above mentioned report coverage parameters are discussed across different regions such as North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the emerging cancer diagnostics market. 

The answers to the following key questions can be found in the report:
•    What are the major drivers, challenges and opportunities of the tumor biomarker test market and their use cases?
•    How is the tumor biomarker test market evolving?
•    What are the market shares of the leading segments of the tumor biomarker test market in 2015?
•    How will each test of the tumor biomarker test grow over the forecast period and how much revenue will these account for in 2023?
•    How will the market shares of the leading national markets change by 2023 and which country will lead the market in 2023?
•    How the industry will evolve during the forecast period between 2016 and 2023?
•    What are the key developmental strategies implemented in different applications across all regions?
•    How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others?
•    Which geographical region will lead the global tumor biomarker test market by the end of the forecast period?
•    Who are the key players in the tumor biomarker test market?
•    What are different application in this market and how are they categorized?
•    What are the market trends and key developments in different geographical regions?
•    What are all market available cancer biomarker test?
•    What is the current market size and future projection for emerging cancer technologies in the major countries?
•    What are the key sources of information about emerging cancer technologies?
•    What is the incidence rate of major cancer type?

The research study tries to answer various aspects of the emerging cancer diagnostics market with the help of central factors driving the market, threats that can possibly slow down the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study takes into account Porter’s Five Force model and opportunity matrix for an in-depth study of the emerging cancer diagnostics market and an assessment of the factors governing the same.

TABLE OF CONTENT
Executive Summary
1 The Research Scope and Methodology
1.1 Scope of the Report
1.2 Global Emerging Cancer Diagnostics Market Research Methodology
2 Introduction to Global Emerging Cancer Diagnostics Market
2.1 Overview
2.2 Analysis of Lifestyle Factors
2.2.1 Obesity/Weight
2.2.2 Physical Activity
2.2.3 Food Habits
2.2.4 Alcohol & Cancer
2.2.4.1 Countries with Highest Consumption of Alcoholic Drinks
2.2.5 Salt Consumption
2.2.6 Breastfeeding
2.3 High and Low Developed Countries
2.3.1 Men
2.3.2 Women
2.4 Data for Cancer Frequency by Country
2.4.1 Men
2.4.2 Women
2.5 Worldwide Cancer Data
2.5.1 Men
2.5.2 Women
3 Market Dynamics
3.1 Market Drivers
3.1.1 Increase in Prevalence Rate of Cancer
3.1.2 Increase in Sedentary Lifestyles
3.1.3 Robust Technological Advancement
3.1.4 Environmental Hazards
3.1.4.1 Five Primary categories of Carcinogens are: -
3.1.5 Government Initiatives and Investment
3.2 Market Challenges
3.2.1 High Capital Investment
3.2.2 Dearth of Skilled Professionals
3.2.3 Lack of Awareness
3.3 Market Opportunities
3.3.1 Nanotechnology Applications in Cancer
3.3.2 3D Printing in Cancer Diagnostics
3.3.3 Robotics in Cancer Diagnostics and Treatment
3.3.4 Fluid Biopsy
3.3.5 Real Time Cancer Diagnostic iKnife
4 Competitive Insights
4.1 Key Market Developments & Strategies
4.1.1 Product Launch and Development
4.1.2 Collaborations, Joint Ventures & Partnerships
4.1.3 Business Expansion and Contracts
4.1.4 Patents, Approvals and Certifications
4.1.5 Mergers and Acquisitions
4.1.6 Other Strategies
4.2 Industry Attractiveness
4.3 Global Market Share Analysis
4.3.1 Market Share Analysis
5 Industry Analysis
5.1 Patent Analysis
5.2 Consortiums, Associations and Regulatory Bodies
6 Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market, Analysis and Forecast
6.1 Assumptions & Limitations for Analysis and Forecast
6.2 Market Overview
6.3 Global Emerging Cancer Diagnostics Market by Tumor Biomarker Test
6.3.1 Prostate Specific Antigen Tests
6.3.2 CTC Tests
6.3.3 Alpha-Fetoprotein (AFP) Tests
6.3.4 CA Test
6.3.4.1 CA 19-9 Tests
6.3.4.2 CA 125 Tests
6.3.5 HER2 Tests
6.3.6 BRCA Test
6.3.7 Anaplastic Lymphoma Kinase (ALK) Tests
6.3.8 EGFR Mutation Tests
6.3.9 KRAS Test
6.3.10 Others
6.3.10.1 National Rental Affordability Scheme (NRAS) Testing
6.3.10.2 RET Gene Testing
6.3.10.3 ROS Testing
6.3.10.4 PIK3CA Tests
6.4 Global Emerging Cancer Diagnostics Market by Application
6.4.1 Lung Cancer
6.4.2 Breast Cancer
6.4.3 Colorectal
6.4.4 Prostate Cancer
6.4.5 Blood Cancer
6.4.5.1 Leukaemia
6.4.5.2 Lymphoma
6.4.5.3 Myeloma
6.4.6 Others
6.5 Global Emerging Technologies in Cancer Diagnostics Market by Geography
6.5.1 North America
6.5.1.1 Country Analysis
6.5.1.1.1 U.S.
6.5.1.1.2 Canada
6.5.2 Europe
6.5.2.1 Countries Having the Highest Cancer Rates
6.5.2.2 Germany
6.5.2.3 France
6.5.2.4 The U.K.
6.5.2.5 Denmark
6.5.2.6 Belgium
6.5.2.7 Norway
6.5.3 APAC
6.5.3.1 India
6.5.3.2 China
6.5.3.3 Japan
6.5.3.4 Australia
6.5.3.5 Singapore
6.5.3.6 Others APAC Region
6.5.4 Rest of the World
6.5.4.1 Middle East
6.5.4.2 Africa
6.5.4.3 South America
7 Company Profiles
7.1 Abbott Laboratories, Inc.
7.1.1 Overview
7.1.2 Financials
7.1.2.1 Financial Summary
7.1.3 SWOT Analysis
7.2 Agilent Technologies
7.2.1 Overview
7.2.2 Financials
7.2.2.1 Financial Summary
7.2.3 SWOT Analysis
7.3 AstraZeneca
7.3.1 Overview
7.3.2 Financials
7.3.2.1 Financial Summary
7.3.3 SWOT Analysis
7.4 Becton Dickinson & Co.
7.4.1 Overview
7.4.2 Financials
7.4.2.1 Financial Summary
7.4.3 SWOT Analysis
7.5 Biocept Inc.
7.5.1 Overview
7.5.2 Financials
7.5.2.1 Financial Summary
7.5.3 SWOT Analysis
7.6 Cancer Genetics Inc.
7.6.1 Overview
7.6.2 Financials
7.6.2.1 Financial Summary
7.6.3 SWOT Analysis
7.7 Danaher Corporation
7.7.1 Overview
7.7.2 Financials
7.7.2.1 Financial Summary
7.7.3 SWOT Analysis
7.8 Foundation Medicine Inc.
7.8.1 Overview
7.8.2 Financials
  Financial Summary
7.8.3 SWOT Analysis
7.9 Illumina Inc.
7.9.1 Overview
7.9.2 Financials
7.9.3 Financial Summary
7.9.4 SWOT Analysis
7.1 LabCorp of America Holdings
7.10.1 Overview
7.10.2 Financials
7.10.2.1 Financial Summary
7.10.3 SWOT Analysis
7.11 Luminex Corporation
7.11.1 Overview
7.11.2 Financials
7.11.2.1 Financial Summary
7.11.3 SWOT Analysis
7.12 Myriad Genetics Inc.
7.12.1 Overview
7.12.2 Financials
7.12.2.1 Financial Summary
7.12.3 SWOT Analysis
7.13 NanoString Technologies Inc.
7.13.1 Overview
7.13.2 Financials
7.13.2.1 Financial Summary
7.13.3 SWOT Analysis
7.14 Neo Genomics Inc.
7.14.1 Overview
7.14.2 Financials
7.14.2.1 Financial Summary
7.14.1 SWOT Analysis
7.15 Quest Diagnostics Incorporated
7.15.1 Overview
7.15.2 Financials
7.15.2.1 Financial Summary
7.15.3 SWOT Analysis
7.16 Qiagen, Inc.
7.16.1 Overview
7.16.2 Financials
7.16.3 Financial Summary
7.16.4 SWOT Analysis
7.17 Roche Holding AG-BR
7.17.1 Overview
7.17.2 Financials
7.17.3 Financial Summary
7.17.4 SWOT Analysis
7.18 Siemens Healthineers
7.18.1 Overview
7.18.2 Financials
7.18.2.1 Financial Summary
7.18.3 SWOT Analysis
7.19 Thermo Fisher Scientific
7.19.1 Overview
7.19.2 Financials
7.19.2.1 Financial Summary
7.19.3 SWOT Analysis
7.2 Snapshot of Other Key Players
7.20.1 Biotheranostics, Inc.
7.20.2 Epigenomics
7.20.3 Exact Sciences Corporation
7.20.4 Ignyta,Inc.
7.20.5 Interpace Diagnostics
7.20.6 Leica Biosystems
7.20.7 BioTime, Inc
7.20.8 Pathway Genomics
7.20.9 Sysmex Corporation
7.20.10 Almac Group
7.20.11 GeneNews Limited (Formerly ChondroGene Limited)
7.20.12 Rosetta Genomics
List of Tables
Table 2.1  Relation Between Obesity & Cancer
Table 2.2  Top 10 Countries with the Highest Percent (%) of Overweight or Obese Adults
Table 2.3  Top Countries with Highest Consumption Alcohol in 2015
Table 2.4  Top 20 Countries with Highest Consumption of Salt in 2015
Table 2.5  Age-Standardised Rate per 100,000 (World)
Table 2.6  Age-Standardized Rate per 100,000 (World)
Table 2.7  Age-Standardised Rate per 100,000 (World)
Table 2.8  Cancer Rate Worldwide in Major Countries
Table 2.9  Cancer Rate in Men
Table 2.10  Cancer Rate in Women
Table 2.11  Worldwide Top Cancer Type Data
Table 2.12  Statistics of Top Cancer Types in Men
Table 2.13  Statistics of Top Cancer Types in Women
Table 2.14  Incidence of Major Type of Cancer
Table 2.15  Incidence of Cancer in Major Countries
Table 4.1  Product Launch and Development
Table 4.2  Collaborations, Joint Ventures & Partnerships
Table 4.3  Business Expansion and Contracts
Table 4.4  Patent and Approvals
Table 4.5  Mergers and Acquisitions
Table 4.6  Others Developments
Table 4.7  Key Factors Considered for Threat of New Entrants
Table 4.8  Key Factors Affecting Bargaining Power of Buyers
Table 4.9  Key Factors Affecting the Bargaining Power of Suppliers
Table 4.10  Key Factors Affecting Threat of Substitute Products
Table 4.11  Key Factors Determining Rivalry among Existing Firms
Table 5.1  Recent Patents of Some Key Players
Table 5.2  Recent Patents of Some Associations/Organizations
Table 5.3  Other Recent Patents
Table 5.4  Examples of Some Regulatory Bodies/Associations/Consortiums
Table 6.1  Key Development and trends
Table 6.2  Key Developments and Trends
Table 6.3  Key Trends and Developments
Table 6.4  Key Trends and Developments
Table 6.5  Key Trends and Developments
Table 6.6  Key Trends and Developments
Table 6.7  Key Trends and Developments
Table 6.8  Key Trends and Development
Table 6.9  Key Trends and Developments
Table 6.10  Key Trends and Developments
Table 6.11  Key Trends and Developments
Table 6.12  Key Trends and Developments
Table 6.13  Key Trends and Development
Table 6.14  Lung Cancer Incidence Data by Major Countries, 2015-2023
Table 6.15  Global Emerging Lung Cancer Diagnostics Market, by Geography, 2015-2023 ($Million)
Table 6.16  Breast Cancer Incidence Data by Major Countries, 2015-2023
Table 6.17  Global Emerging Breast Cancer Diagnostics Market, by Geography, 2015-2023 ($Million)
Table 6.18  Colorectal Cancer Incidence Data by Major Countries, 2015-2023
Table 6.19  Global Emerging Lung Cancer Diagnostics Market, by Geography, 2015-2023 ($Million)
Table 6.20  Prostate Cancer Incidence Data by Major Countries, 2015-2023
Table 6.21  Global Emerging Prostate Cancer Diagnostics Market, by Geography, 2015-2023 ($Million)
Table 6.22  Leukaemia Cancer Incidence Data by Major Countries, 2015-2023
Table 6.23  Non-Hodgkin Lymphoma Cancer Incidence Data by Major Countries, 2015-2023
Table 6.24  Myeloma Cancer Incidence Data by Major Countries, 2015-2023
Table 6.25  Global Emerging Blood Cancer Diagnostics Market, by Geography, 2015-2023 ($Million)
Table 6.26  Global Emerging Lung Cancer Diagnostics Market, by Geography, 2015-2023 ($Million)
Table 6.27  Stomach Cancer Incidence Data by Major Countries, 2015-2023
Table 6.28  Liver Cancer Incidence Data by Major Countries, 2015-2023
Table 6.29  Cervical Cancer Incidence Data by Major Countries, 2015-2023
Table 6.30  Oesophagus Cancer Incidence Data by Major Countries, 2015-2023
Table 6.31  Ovarian Cancer Incidence Data by Major Countries, 2015-2023
List of Figures
Figure 1  Relation between the Total Population and Cancer Population Worldwide
Figure 2  Global Emerging Cancer Diagnostics Market ($Billion), 2015-2023
Figure 3  Global Emerging Cancer Diagnostics Market by Tumor Test ($Million), 2016-2023
Figure 4  Global Emerging Cancer Diagnostics Market by Application ($Million), 2016-2023
Figure 5  Global Emerging Cancer Diagnostics Market by Geography ($Million), 2016-2023
Figure 1.1  Global Emerging Cancer Diagnostics Market Scope
Figure 1.2  Research Methodology
Figure 1.3  Secondary Data Sources
Figure 1.4  Top Down and Bottom Up Approach
Figure 1.5  Global Emerging Cancer Diagnostics Market Influencing Factors
Figure 1.6  Assumptions and Limitations
Figure 3.1  Global Emerging Technologies in Cancer Diagnostics Market: Market Dynamics
Figure 3.2  Prevalence of Cancer in Developed & Developing Countries
Figure 4.1  Recent Market Development Strategy Snapshot Analysis
Figure 4.2  Key Market Developments & Strategies
Figure 4.3  Porter’s Five Forces Analysis
Figure 4.4  Market Share Analysis, 2015
Figure 6.1  Global Emerging Cancer Diagnostics Market Classification
Figure 6.2  Global Emerging Cancer Diagnostics Market, 2015-2023 ($Billion)
Figure 6.3  Tumor Biomarker Tests Applications
Figure 6.4  Tumor Biomarker Tests
Figure 6.5  Global Emerging Cancer Diagnostics Market, by Tumor Test, 2015-2023 ($Billion)
Figure 6.6  Global Emerging Cancer Diagnostics Market, by PSA Test, 2015-2023 ($Million)
Figure 6.7  Global Emerging Cancer Diagnostics Market, by CTC Test, 2015-2023 ($Million)
Figure 6.8  Global Emerging Cancer Diagnostics Market, by AFP Test, 2015-2023 ($Million)
Figure 6.9  Global Emerging Cancer Diagnostics Market, by CA Test, 2015-2023 ($Million)
Figure 6.10  Global Emerging Cancer Diagnostics Market, by HER2 Test, 2015-2023 ($Million)
Figure 6.11  Global Emerging Cancer Diagnostics Market, by BRCA Test, 2015-2023 ($Million)
Figure 6.12  Global Emerging Cancer Diagnostics Market, by ALK Test, 2015-2023 ($Million)
Figure 6.13  Global Emerging Cancer Diagnostics Market, by EGFR Test, 2015-2023 ($Million)
Figure 6.14  Global Emerging Cancer Diagnostics Market, by KRAS Test, 2015-2023 ($Million)
Figure 6.15  Types of Cancer
Figure 6.16  Global Emerging Cancer Diagnostics Market, by Application, 2015-2023 ($Billion)
Figure 6.17  Types of Lung Cancer
Figure 6.18  Global Emerging Lung Cancer Diagnostics Market, by Test, 2016 and 2023
Figure 6.19  Global Emerging Breast Cancer Diagnostics Market, by Test, 2016 and 2023
Figure 6.20  Global Emerging Colorectal Cancer Diagnostics Market, by Test, 2016 and 2023
Figure 6.21  Global Emerging Prostate Cancer Diagnostics Market, by Test, 2016 and 2023
Figure 6.22  Global Emerging Blood Cancer Diagnostics Market, by Test, 2016 and 2023
Figure 6.23  Global Emerging Cancer Diagnostics Market by Geography
Figure 6.24  Drivers and Challenges
Figure 6.25  Key Regulatory Bodies, Consortiums & Associations
Figure 6.26  U.S. Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.27  Drivers and Challenges
Figure 6.28  Key Regulatory Bodies, Consortiums and Associations
Figure 6.29  Canada Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.30  Cancer Incidence Data in Canada
Figure 6.31  Drivers and Challenges
Figure 6.32  Key Regulatory Bodies, Consortiums and Associations
Figure 6.33  Drivers and Challenges
Figure 6.34  Key Regulatory Bodies, Consortiums and Associations
Figure 6.35  Germany Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.36  Drivers and Challenges
Figure 6.37  Key Regulatory Bodies, Consortiums and Associations
Figure 6.38  France Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.39  Drivers and Challenges
Figure 6.40  Key Regulatory Bodies, Consortiums and Associations
Figure 6.41  U.K. Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.42  Cancer Incidence Data in U.K.
Figure 6.43  Drivers and Challenges
Figure 6.44  Key Regulatory bodies, Consortiums, Associations
Figure 6.45  Denmark Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.46  Cancer Incidence Data in Denmark
Figure 6.47  Drivers and Challenges
Figure 6.48  Key Regulatory Bodies, Consortiums and Associations
Figure 6.49  Key Regulatory Bodies, Consortiums and Associations
Figure 6.50  Drivers and Challenges
Figure 6.51  Key Regulatory Bodies, Consortiums and Associations
Figure 6.52  APAC Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.53  APAC Emerging Cancer Diagnostics Market by Countries, 2015-2023
Figure 6.54  Drivers and Challenges
Figure 6.55  Regulatory Bodies, Consortiums and Associations
Figure 6.56  India Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.57  Cancer Incidence Data in India
Figure 6.58  Drivers and Challenges
Figure 6.59  Regulatory Bodies, Consortiums and Associations
Figure 6.60  Drivers and Challenges
Figure 6.61  Key Regulatory Bodies, Consortiums and Associations
Figure 6.62  Japan Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.63  Cancer Incidence Data in Japan
Figure 6.64  Drivers and Challenges
Figure 6.65  Key Regulatory Bodies, Consortiums and Associations
Figure 6.66  Australia Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.67  Drivers and Challenges
Figure 6.68  Key Regulatory Bodies, Consortiums and Associations
Figure 6.69  Singapore Emerging Cancer Diagnostics Market, 2015-2023
Figure 6.70  Drivers and Challenges
Figure 6.71  Key Regulatory Bodies, Consortiums and Associations
Figure 6.72  Key Regulatory Bodies, Consortiums and Associations
Figure 6.73  Key Regulatory Bodies, Consortiums and Associations
Figure 6.74  Key Consortiums and Associations
Figure 7.1  Abbott Laboratories: Overall Financials (2013-2016)
Figure 7.2  Abbott Laboratories: Net Revenue by Business Segment (2013-2016)
Figure 7.3  Abbott Laboratories: Net Revenue by Diagnostics Segment, 2016
Figure 7.4   Abbott Laboratories: Net Revenue by Geographies (2013-2016)
Figure 7.6  Agilent: Overall Financials, (2013-2016)
Figure 7.7  Agilent: Net Revenue by Business Segment, (2014-2016)
Figure 7.8  Agilent: Revenue Across Different Geographies, (2013-2015)
Figure 7.9  Agilent Technologies: SWOT Analysis
Figure 7.10  AstraZeneca: Overall Financials, (2013-2015)
Figure 7.11  AstraZeneca: Revenue Across Different Geographies, (2013-2015)
Figure 7.12  AstraZeneca: SWOT Analysis
Figure 7.13  Becton Dickinson & Co.: Overall Financials, (2013-2016)
Figure 7.14  Becton Dickinson & Co.: Revenue across Different Geographies, (2013-2016)
Figure 7.15  BD & Co.: Net Revenue by Business Segment, (2013-2016)
Figure 7.16  BD & Co.: SWOT Analysis
Figure 7.17  Biocept, Inc.: Overall Financials, (2013-2015)
Figure 7.18  Biocept Inc.: SWOT Analysis
Figure 7.19  Cancer Genetics Incorporated: Overall Financials, (2013-2015)
Figure 7.20  Cancer Genetics Inc.: SWOT Analysis
Figure 7.21  Danaher: Overall Financials, (2013-2015)
Figure 7.22  Danaher: Revenue Across Different Geographies, (2013-2015)
Figure 7.23  Danaher: Net Revenue by Business Segment, (2013-2015)
Figure 7.24  Danaher: SWOT Analysis
Figure 7.25  Foundation Medicine: Overall Financials, (2013-2015)
Figure 7.26  Foundation Medicine Inc.: SWOT Analysis
Figure 7.27  Illumina: Overall Financials, (2013-2015)
Figure 7.28  Illumina: Net Revenue by Business Segment, (2013-2015)
Figure 7.29  Illumina: Revenue Across Different Geographies, 2013-2015
Figure 7.30  Illumina Inc.: SWOT Analysis
Figure 7.31  LabCorp: Overall Financials, 2013-2015
Figure 7.32  LabCorp: Net Revenue by Business Segment, 2013-2015
Figure 7.33  LabCorp: SWOT Analysis
Figure 7.34  Luminex Corporation: Overall Financials, (2013-2015)
Figure 7.35  Luminex Corporation: Revenue Across Different Geographies, (2013-2015)
Figure 7.36  Luminex Corporation: SWOT Analysis
Figure 7.37  Myriad Genetics: Overall Financials, (2013-2016)
Figure 7.38  Myriad Genetics: Net Revenue by Business Segments, (2013-2016)
Figure 7.39  Myriad Genetics Inc.: SWOT Analysis
Figure 7.40  NanoString Technologies: Overall Financials, (2013-2015)
Figure 7.41  NanoString Technologies: Revenue Across Different Geographies, (2013-2015)
Figure 7.42  NanoString Technologies, Inc.: SWOT Analysis
Figure 7.43  Neo Genomics, Inc.: Overall Financials, (2013-2015)
Figure 7.44  Neo Genomics Inc.: SWOT Analysis
Figure 7.45  Quest Diagnostics: Overall Financials, (2013-2015)
Figure 7.46  Quest Diagnostics: Net Revenue by Business Segments, (2013-2015)
Figure 7.47  Quest Diagnostics: SWOT Analysis
Figure 7.48  Qiagen, Inc.: Overall Financials, (2013-2015)
Figure 7.49  Qiagen, Inc.: Revenue Across Different Geographies, (2013-2015)
Figure 7.50  Qiagen, Inc.: Net Revenue by Business Segments, (2013-2015)
Figure 7.51  Qiagen, Inc.: SWOT Analysis
Figure 7.52  Roche: Overall Financials, (2013-2015)
Figure 7.53  Roche: Revenue Across Different Geographies, (2013-2015)
Figure 7.54  Roche: Net Revenue by Business Segment, (2013-2015)
Figure 7.55  Roche: SWOT Analysis
Figure 7.56  Siemens Healthineers: Overall Financials, (2013-2016)
Figure 7.57  Siemens Healthineers: Revenue Across Different Geographies, (2013-2016)
Figure 7.58  Siemens Healthineers: Net Revenue by Business Segment, (2014-2016)
Figure 7.59  Siemens Healthineers: SWOT Analysis
Figure 7.60  Thermo Fisher Scientific: Overall Financials, (2013-2015)
Figure 7.61  Thermo Fisher Scientific: Net Revenue by Business Segments, (2013-2015)
Figure 7.62  Thermo Fisher Scientific: Net Revenue by Geography, (2013-2015)
Figure 7.63  Thermo Fisher Scientific: SWOT Analysis

Cancer is one of the most modernized trends in the healthcare industry. It has shown substantial progress in the last few years being the most commonly found chronic disease which affects, more or less, people of all age groups. The growth of the cancer diagnostics market is attributed majorly to the rapid increase in the oncology population, integration of smart devices with medical devices and advancement of healthcare technologies. The gradual advancement and innovation of new cancer care technologies are contributing to developing a concrete platform for further growth of cancer diagnostics market. With the emergence of advanced technologies such as precision medicine, biomarkers, companion diagnostics, and liquid biopsy into the field of cancer diagnostics, there has been a gradual rise in the overall demand of the newly developed products. Presently, the main focus of government initiatives is mainly towards developing effective solutions, controlling the level of increase in cancer-stricken population, and integrating advanced technologies to fulfil the unmet needs of the patients. 

In 2015, it was found that approximately 15 million of the world’s population is suffering from this disease and is estimated to reach the double number of patients by the end of 2030.  The following figure shows the relation between the total population and cancer population worldwide.

Figure 1
Relation between the Total Population and Cancer Population Worldwide

Relation between the Total Population and Cancer Population Worldwide

 BIS Research Analysis

There are high chances that the ageing population currently suffering from cancer is also prone to higher risks of complications from this disease such as heart attacks, weak immune systems, kidney failure, amputation and blindness among others. All these issues can be resolved through effective cancer care solutions by providing education and support to patients with chronic conditions. The demand for cancer diagnostics tests are increasing every year due to its easy availability and effectiveness. The global emerging cancer diagnostics market has been identified as one of the fastest growing industries, owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among a plethora of public companies.

There is a high prevalence of cancer in low and middle-income countries. This prevalence can be effectively controlled by following simple life measures such as indulging in physical activities, avoiding junk food, avoiding direct sunlight contact, and retaining normal body weight, among others. Governmental regulations and standards play a major role in sustaining the growth and development of the market. The main aim of these regulations is to make diagnostics tests more adaptable and focused towards different types of cancer and also provide modern technologies to the needed people. The patients benefit indirectly through these regulations as it helps them save time and cuts-down the overall cost as the patients receive the required treatment for the disease. 

The global emerging cancer diagnostics market is expected to grow at a CAGR of 13.45% from 2016 to 2023 and reach a figure of $6.34 billion by 2023. The advancements in technology, adoption of biomarker tests, and increasing cancer incidence rate are some of the major driving factors for this market. The global emerging cancer diagnostics market has been classified on the basis of test type, application and geography. 

On the basis of the test type, the emerging cancer diagnostics can be segmented in different parts. Among which HER2Test is dominating followed by PSA Tests. There are different types of biomarkers which are used in diagnosis to know the responsible gene for specific cancer type. However, CA Tests, ALK Tests and BRCA Tests are also growing at high rate.

There are many types of cancer, but in this report top 20 cancer type has been mentioned. Out of this five cancer types are dominating for which these tests are being used. These are Lung, breast, Colorectal, Prostate and Blood Cancer. However, Stomach, Oesophagus, Ovarian and Cervical Cancer are showing high incidence rate in future.

Patents and approvals are essential tools for the companies operating in this market as it helps in gaining the confidence and trust of patient. As the industry evolves, the role of consortiums and regulatory bodies becomes pivotal in shaping the future trajectory. These regulations and compliances help in the increasing adoption of tests and their applications among patient. In this report many recent key developments and market trends have been mentioned. Also, a huge list of key players are given in the report. Some of the key players are Roche, Thermo Fisher, Agilent, Quest Diagnostics, and Illumina Inc. among others.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields

OUR HAPPY CLIENTS


related reports

 

OUR CLIENTS